Global Postmenopausal Osteoporosis Market Research & Forecast (2018-2023) - ResearchAndMarkets.com
The "Global Postmenopausal Osteoporosis Market Research and Forecast 2018-2023" report has been added to ResearchAndMarkets.com's offering.
The postmenopausal osteoporosis market is expected to grow significantly during the forecast period (2018-2023).
The global postmenopausal osteoporosis market is significantly growing due to some factors which include increasing geriatric population. Age is the major factor for the cause of the osteoporosis disease, hence rising geriatric population contributes in the market growth. Factors such as growing prevalence of osteoporosis and developing healthcare infrastructure across the globe also drive the growth of the segment.
Changing lifestyle of people due to consumption of alcohol and smoking, mounting awareness among people through awareness initiatives and programs and continuous innovations in the drugs with the approval by the FDA creates the future opportunity for the growth of the market. On the other hand, there are various factors acting as the barriers for the market which includes the requirement of high standards for the approval of new product launch and increasing competition from the generics.
Global postmenopausal osteoporosis market can be segmented on the basis of treatment and distribution channel. Based on the treatment, the market can be further diversified as bisphosphonates, hormones, strontium ranelate, raloxifene and denosumab.
Among the treatment, bisphosphonates segment is expected to lead the market as it is extensively used for the prevention and treatment of postmenopausal osteoporosis.
Furthermore, on the basis of distribution channel, the market can be bifurcated as hospital pharmacies, retail pharmacies and E-commerce pharmacies.
1. Report Summary
2. Market Overview & Insights
3. Market Determinant
4. Market Segmentation
5. Competitive Landscape
6. Regional Analysis
7. Company Profiles
- Deltanoid Pharmaceuticals
- Eli Lilly & Company
- Enteris Biopharma
F. Hoffmann-La Roche
- Ligand Pharmaceuticals
- Merck & Co.
- Noven Pharmaceuticals
- Novo Nordisk A/S
- Paras Biopharmaceuticals Finland Oy
- Phytohealth Corporation
- Procter & Gamble
- Tarsa Therapeutics
Teva Pharmaceuticals Industries
For more information about this report visit https://www.researchandmarkets.com/research/qjqp3q/global?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20190115005435/en/